# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k073055   
B. Purpose for Submission: New device   
C. Measurand: Creatinine   
D. Type of Test: Quantitative   
E. Applicant: Dade Behring, Inc.   
F. Proprietary and Established Nam Dimension $^ \mathrm { \textregistered }$ Enzymatic Creatinine (ECRE) Flex   
G. Regulatory Information:

$^ \mathrm { \textregistered }$ Reagent Cartridge (DF270)

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>JFY</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR§ 862.1225Creatinine test system</td><td rowspan=1 colspan=1>75 - ClinicalChemistry</td></tr></table>

# H. Intended Use:

1. Intended use(s): See Indications for Use below

2. Indication(s) for use:

The ECRE method is an in vitro diagnostic test for the quantitative measurement of creatinine in human serum, plasma and urine on the Dimension $^ \mathrm { \textregistered }$ clinical chemistry system. Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis and as a calculation basis for other urine analytes.

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: Dimension $^ \mathrm { \textregistered }$ Clinical Chemistry System

# I. Device Description:

The Dimension $^ \mathrm { \textregistered }$ ECRE Flex $^ \mathrm { \textregistered }$ reagent cartridge is a prepackaged in-vitro diagnostic test method that is specifically designed to be used on the Dade Behring Dimension $^ \mathrm { \textregistered }$ Clinical Chemistry System. The reagents contained in the Dimension $^ \mathrm { \textregistered }$ ECRE Flex $^ \mathrm { \textregistered }$ reagent cartridge are: Reagent 1 contains TAPS buffer, creatinase, sarcosine oxidase and HTIB; Reagent 2 contains TAPS buffer, creatininase, horseradish peroxidase, 4-aminophenazon and potassium hexacyanoferrate (II).

# J. Substantial Equivalence Information:

<table><tr><td colspan="1" rowspan="1">Feature</td><td colspan="1" rowspan="1">Dimension® ECRE Flex®reagent cartridge</td><td colspan="1" rowspan="1">Roche Creatinine Plus Reagent(K003261)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The ECRE method is an in vitrodiagnostic test for thequantitative measurement ofcreatinine in human serum,plasma, and urine on theDimension® clinical chemistrysystem. Creatininemeasurements are used in thediagnosis and treatment of renaldiseases, in monitoring renaldialysis, and as a calculationbasis for other urine analytes.</td><td colspan="1" rowspan="1">Enzymatic in vitro assay for thedirect quantitative determination ofcreatinine in human serum, plasmaand urine using Roche clinicalchemistry analyzers.</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Plasma, serum, and urine.</td><td colspan="1" rowspan="1">Human serum, plasma and urine.</td></tr><tr><td colspan="1" rowspan="1">Measuring</td><td colspan="1" rowspan="1">0.03 -20.00 mg/dL</td><td colspan="1" rowspan="1">0.03 - 30 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Range</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Y</td></tr><tr><td colspan="1" rowspan="1">Sample Size</td><td colspan="1" rowspan="1">6 μL</td><td colspan="1" rowspan="1">6 μL</td></tr><tr><td colspan="1" rowspan="1">Measurement</td><td colspan="1" rowspan="1">Bichromatic end point</td><td colspan="1" rowspan="1">Bichromatic end point</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP5-A2: Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Second Edition (2004)   
CLSI EP6-A: Evaluation of Linearity of Quantitative Measurement Procedures, A Statistical Approach: Approved Guideline (2003)   
CLSI EP7-A: Interference Testing in Clinical Chemistry; Approved Guideline (2002) CLSI EP17-A: Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline (2004)   
CLSI EP9-A2: Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline (2002)

# L. Test Principle:

The Creatinine Assay is based on an enzymatic reaction. In TAPS buffer creatinine is hydrolyzed by creatininase to creatine, which is than hydrolyzed by creatinase to sarcosine. Sarcosine oxidase hydrolyzes sarcosine to glycine, formaldehyde and peroxide. During the reaction peroxide and a chromogen form a colored end product that is proportional to the amount of creatinine in the sample and is measured at 510 and $7 0 0 \mathrm { n m }$ using a bichromatic end point.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Reproducibility studies were conducted by testing two levels of a commercially available control, serum pool and a urine pool. The samples were run in duplicate, twice a day for twenty days using one lot and one instrument. The results are presented in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Reproducibility</td><td rowspan=1 colspan=2>Within-Lab</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>mg/dL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Serum pool 1</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Serum pool 2</td><td rowspan=1 colspan=1>1.55</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>Control Level 1</td><td rowspan=1 colspan=1>.79</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>Control Level 2</td><td rowspan=1 colspan=1>5.80</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Urine pool 1</td><td rowspan=1 colspan=1>66.45</td><td rowspan=1 colspan=1>1.41</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.36</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>Urine pool 2</td><td rowspan=1 colspan=1>203.13</td><td rowspan=1 colspan=1>3.38</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>4.07</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Control Level 1</td><td rowspan=1 colspan=1>73.14</td><td rowspan=1 colspan=1>0.91</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.82</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>Control Level 2</td><td rowspan=1 colspan=1>164.90</td><td rowspan=1 colspan=1>1.97</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>4.68</td><td rowspan=1 colspan=1>2.8</td></tr></table>

# b. Linearity/assay reportable range:

The reportable range of the assay is $0 . 3 - 2 0 \mathrm { m g / d L }$ . The urine measuring range goes to $2 0 0 \mathrm { m g / d L }$ due to the dilution 1:10 of the sample before it is analyzed. The range is based on linearity, detection limit and method comparison. Linearity across the assay range was confirmed for serum samples by inter diluting a sample spiked (high sample) with anhydrous creatinine with a sample having a low endogenous creatinine to create seven additional samples. The Chem I calibrator was used as the zero sample. A high urine sample was made by spiking it with anhydrous creatinine. Additional samples were made by diluting the high sample with deionized water to create six additional samples. Deionized water was used as the zero sample. Five determinations of each pool were tested and a linear regression analysis was performed by the method of least squares. The instrument generates a flag which states “Above Assay Range” or "Below Assay Range". In addition to this, automatic dilutions are performed by the instrument for results that fall outside the assay range. Automatic dilutions are defined in the method parameters and cannot be changed by an operator. The results are presented below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Serum</td><td rowspan=1 colspan=2>Urine</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Theor.ETOHmg/dL</td><td rowspan=1 colspan=1>ObservedETOHmg/dL</td><td rowspan=1 colspan=1>Theor.ETOHmg/dL</td><td rowspan=1 colspan=1>ObservedETOHmg/dL</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>-0.03</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>-0.21</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>.76</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>6.62</td><td rowspan=1 colspan=1>6.56</td><td rowspan=1 colspan=1>5.12</td><td rowspan=1 colspan=1>4.82</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>12.28</td><td rowspan=1 colspan=1>12.31</td><td rowspan=1 colspan=1>25.60</td><td rowspan=1 colspan=1>26.79</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>17.95</td><td rowspan=1 colspan=1>17.80</td><td rowspan=1 colspan=1>51.21</td><td rowspan=1 colspan=1>54.25</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>22.00</td><td rowspan=1 colspan=1>23.60</td><td rowspan=1 colspan=1>102.41</td><td rowspan=1 colspan=1>109.91</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>31.90</td><td rowspan=1 colspan=1>30.82</td><td rowspan=1 colspan=1>153.62</td><td rowspan=1 colspan=1>161.54</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>41.82</td><td rowspan=1 colspan=1>40.55</td><td rowspan=1 colspan=1>206.00</td><td rowspan=1 colspan=1>212.65</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>52.06</td><td rowspan=1 colspan=1>50.33</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>65.00</td><td rowspan=1 colspan=1>62.91</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=2>.9631</td><td rowspan=1 colspan=2>1.042</td></tr><tr><td rowspan=1 colspan=1>intercept</td><td rowspan=1 colspan=2>.45</td><td rowspan=1 colspan=2>.32</td></tr><tr><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=2>.999</td><td rowspan=1 colspan=2>.999</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

This device does not include calibrators or controls. The sponsor recommends using calibrators by Dade Behring Inc. Dimension Chem I Calibrator, Catalog Number DC18B cleared k0611838.

# d. Detection limit:

The Limit of Blank and Limit of Detection were determined by running a low sample (two different samples) and true blank sample for 4 days, 4 replicates/day, for each sample. The testing was split between two instruments and lots of reagents. The detection limit is $0 . 3 \mathrm { m g / d L }$ Creatinine

# e. Analytical specificity:

The Dimension ECRE assay was evaluated for interference according to CLSI EP7- A2. The following substances demonstrated no significant bias (defined as $< 1 0 \%$ ).

<table><tr><td colspan="1" rowspan="1">SubstanceTested</td><td colspan="1" rowspan="1">Substanceconcentration</td><td colspan="1" rowspan="1">EthylAlcoholmg/dL</td><td colspan="1" rowspan="1">Bias %</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin(hemolysate)</td><td colspan="1" rowspan="1">300 mg/dL/Hemoglobin</td><td colspan="1" rowspan="1">1.00</td><td colspan="1" rowspan="1">&lt;10</td></tr><tr><td colspan="1" rowspan="1">Bilirubin(unconjugated)</td><td colspan="1" rowspan="1">23 mg/dL</td><td colspan="1" rowspan="1">1.00</td><td colspan="1" rowspan="1">&lt;10</td></tr><tr><td colspan="1" rowspan="1">Bilirubin(conjugated)</td><td colspan="1" rowspan="1">20 mg/dL</td><td colspan="1" rowspan="1">1.00</td><td colspan="1" rowspan="1">&lt;10</td></tr><tr><td>Lipemia (Intralipid)</td><td>3000 mg/dL</td><td>1.22</td><td>&lt;10</td></tr></table>

An extensive list of other compounds was evaluated for interference and found to have no significant interference or cross reactivity. A list of these compounds is present in the product labeling.

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device:

A split sample method comparison was conducted between the Dimension ECRE and Roche CREA Plus. The assays were performed following CLSI EP9-A2. The correlations are as follows:

<table><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Device range(mg/dL)</td><td rowspan=1 colspan=1>Predicaterange(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>1.03</td><td rowspan=1 colspan=1>-0.03</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>0.64-18.95</td><td rowspan=1 colspan=1>0.61-18.58</td></tr><tr><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>-2.29</td><td rowspan=1 colspan=1>0.994</td><td rowspan=1 colspan=1>14.4-172.5</td><td rowspan=1 colspan=1>14.1-163</td></tr></table>

# b. Matrix comparison:

A serum / plasma comparison test was performed for the Dimension $^ \mathrm { \textregistered }$ ECRE Flex $^ \mathrm { \textregistered }$ assay. Thirty-three serum samples were compared to the following two anticoagulants Sodium and Lithium Heparin. The correlations are as follows:

<table><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Device range(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>Na Heparin vs.Serum</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>1.03</td><td rowspan=1 colspan=1>-0.04</td><td rowspan=1 colspan=1>.999</td><td rowspan=1 colspan=1>0.5-17.5</td></tr><tr><td rowspan=1 colspan=1>Li Heparin vs.Serum</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>-0.05</td><td rowspan=1 colspan=1>0.999</td><td rowspan=1 colspan=1>0.5-17.9</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not applicable   
$b$ . Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

The creatinine reference range was obtained from the literature. Package insert states that each laboratory should establish its own expected ranges.

Serum/plasma:

Males $0 . 6 7 { - } 1 . 1 7 \ \mathrm { m g / d L }$ , $5 9 { \mathrm { - } } 1 0 4 \ \mu \mathrm { m o l / L }$ Females $0 . 5 1 - 0 . 9 5 \mathrm { m g / d L }$ , $4 5 { - } 8 4 ~ \mathrm { \mu m o l / L }$ Combined $0 . 5 1 { - } 1 . 1 7 \mathrm { m g / d L }$ , $4 5 { \mathrm { - } } 1 0 4 \ \mu \mathrm { m o l / L }$

Random Urine:

Males 40-278 mg/dL, 3536-24575 μmol/L Females 29-226 mg/dL, 2564-19978 μmol/L Combined 29-278 mg/dL, 2564-24575 μmol/L

24 Hour Urine Excretion Males 0.87-2.41 g/day, 8-21 mmol/day Females 0.67-1.50 g/day, 6-14 mmol/day

Mazzachi BC, Peake MJ, Ehrhardt V, Reference range and method comparison studies for enzymatic and Jaffe creatinine assays in plasma and serum an early morning urine, Clin Lab 2000; 46: 53-55.

Junge W, Wilke B, Haladi A, Klein G, Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and modified Jaffe method, Clinica Chimica Acta 2004; 344; 137-148.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.